Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Beam Therapeutics

Evaluate

Thumbnail
May 09, 2023

Gene editing: overhyped or unstoppable tide?

A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.

Thumbnail
February 23, 2023

Sickle cell pipeline gets edited down

Article image
Vantage logo
February 16, 2023

Why Verve investors might hope for hold resolution soon

Article image
Vantage logo
January 06, 2023

Will Graphite's blow-up add to FDA caution over gene editing?

Article image
Vantage logo
January 05, 2023

Flotations fail to bounce back

2022 saw just 19 initial public offerings of drug developers, the lowest total since 2012.

Article image
Vantage logo
November 09, 2022

Ash 2022 preview – waiting for Editas

Data on the group’s sickle cell project do not feature in the regular abstracts, while Bluebird walks away from its short hairpin contender.

Article image
Vantage logo
November 07, 2022

Verve hit by FDA’s gene editing caution

Article image
Vantage logo
August 31, 2022

Beam's base case under the spotlight

Article image
Vantage logo
August 24, 2022

Foghorn sounds another warning about the class of ‘20

In 2020 76 biotech floats raised a combined $12.7bn. Foghorn is not the first to show that much of the faith was misplaced.

Article image
Vantage logo
July 21, 2022

Vertex gets more in vivo gene editing Verve

Article image
Vantage logo
January 28, 2022

The year of the small buyout

Biopharma takeouts in the $1-5bn range jumped in 2021, as rising valuations made their mark.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

May 15, 2023

Pharma’s Biggest Spenders 2022 Infographic

May 03, 2023

Gene Editing: Overhyped or Unstoppable Tide?

View more...

Editor's Picks

Vantage logo
May 16, 2023

Heightened US antitrust fears rattle biopharma

Vantage logo
May 11, 2023

2023’s biggest launches: the story so far

Vantage logo
May 17, 2023

Viking’s Voyage is not over yet

Vantage logo
May 09, 2023

Gene editing: overhyped or unstoppable tide?

Vantage logo
May 16, 2023

A slow (and low) year for FDA approvals

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up